Kilambi News
Thursday, November 19, 2026

Teva research chief Eric Hughes resigns with immediate effect

Life Sciences Thursday, November 19, 2026 - Updated Nov 19, 2026 01:44

Dr. Eric Hughes, Teva's executive vice president for global research and development and its chief medical officer, notified the company on November 17 of his intention to resign and steps down immediately, Teva disclosed in an SEC filing.

Why it matters: Hughes ran the pipeline side of the world's largest generics maker, and his immediate departure, with no successor named in the filing, leaves the top research job open while he assists with the transition over the next few months.

Data as of Teva Form 8-K filed with the SEC on November 18, 2026 (event date November 17, 2026), read in full from the filing's own text; accession 0001193125-26-467276. All wording is the filing's own. Developing item.

Teva Pharmaceutical Industries said in an SEC filing that Dr. Eric Hughes, its executive vice president for global research and development and chief medical officer, notified the company on November 17 of his intention to resign. Hughes steps down from the role immediately and will continue to assist with the transition over the next few months.

Teva announced the departure in a press release on November 18, furnished with the filing. The 8-K names no successor and gives no reason for the resignation.

Sources

  1. Teva Pharmaceutical Industries Ltd. Form 8-K, November 17, 2026 (accession 0001193125-26-467276) - SEC EDGAR - 2026-11-18